argenx Unnatural Products Acquisition: Inside the $1.15B Bet on Oral Peptides
argenx will buy Unnatural Products for up to $1.15B ($550M upfront) to own an oral macrocyclic peptide platform. Terms, strategy, risks and market context.
Get the latest industry insights and trends in the pharmaceutical sector with Med Pharma News. Stay informed about groundbreaking research, regulatory updates, and market analysis.
argenx will buy Unnatural Products for up to $1.15B ($550M upfront) to own an oral macrocyclic peptide platform. Terms, strategy, risks and market context.
How to read healthcare startup investment India data for October 2026: a reported $173 million, concentration in one deal and why trackers disagree.
Why Apollo Hospitals revenue rose 23% in Q2 FY27, how profit and occupancy compare, and what the 5,800-bed plan means for margins and returns.
Why early cancer detection is a market test case: the NHS STRIDE trial, £8.49m public funding and a diagnostics sector Acumen sizes at USD 142.3bn.
The latest measles cases USA November 2026 reports, led by a New York child death, raise questions for vaccine makers and public health budgets.
The Narayana Health Q2 results FY27: 73% revenue growth, 22.6% without the UK. A business look at margins, finance costs and what to watch.
The Rainbow Children Q2 FY27 results: revenue up 23%, profit up 11%. A business look at expansion costs, margins and what comes next.
The Assam proton therapy centre is a ₹600 crore public bet. Financing split, utilisation questions and execution risks.
Who captures India pharmaceutical market growth 2026? Sun, Torrent and Mankind outgrew the 12% market. Pricing and caveats.